Journals / Medicine Science / 2014 / Cilt: 3 - Sayı: 1

The Incidence of Upper Gastrointestinal Complications of Non-steroidal Anti-inflammatory Drugs in Elderly Patients

Pages
1032–1045
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The study concluded that Celecoxib was safer than Meloxicam than Ibuprofen on the upper gastrointestinal tract.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The incidence of upper gastrointestinal (GI) complications of non-steroidal anti-inflammatory drugs remains the most common side effect.
📊
Key Findings & Data:This study included 4 groups of subjects aging above 50 years old divided into control group including 10 healthy volunteers suffering from the symptom of dyspepsia and three test groups, each test group included 10 osteoarthritic or rheumatic patients receiving only one NSAIDs (Ibuprofen, Celecoxib or Meloxicam) from at least 1 month.
💡
Conclusion & Impact:The study concluded that Celecoxib was safer than Meloxicam than Ibuprofen on the upper gastrointestinal tract.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The incidence of upper gastrointestinal (GI) complications of non-steroidal anti-inflammatory drugs remains the most common side effect. The objective of this study was to compare the incidence of upper gastrointestinal complications of Ibuprofen as non-selective non-steroidal anti-inflammatory drug (NSAID) to Celecoxib and Meloxicam as selective non-steroidal antiinflammatory drugs. This study included 4 groups of subjects aging above 50 years old divided into control group including 10 healthy volunteers suffering from the symptom of dyspepsia and three test groups, each test group included 10 osteoarthritic or rheumatic patients receiving only one NSAIDs (Ibuprofen, Celecoxib or Meloxicam) from at least 1 month. There was a statistically highly significant difference between the studied groups regarding the incidence of dyspepsia (p-value=0.008) and regarding the incidence of gastritis (p-value=0.042). In group II, there was a statistically significant correlation between the duration of administration of Ibuprofen and the incidence of dyspepsia. Similarly, in group III, there was a statistically significant correlation between the duration of administration of Celecoxib and the incidence of dyspepsia. Controversial, in group IV, there was no statistically significant correlation between the duration of administration of Meloxicam and the incidence of dyspepsia or gastritis or ulcer. Incidence of gastrointestinal side effects was lower for Celecoxib than for Meloxicam than for Ibuprofen. The study concluded that Celecoxib was safer than Meloxicam than Ibuprofen on the upper gastrointestinal tract.

🔖

Cite This Article

HASSANEİN, A. H. A., ABDELRAHİM, M. A. E., SAİD, A. S. A., HUSSEİN, R. R. S., ABUSEİF, M. (2014). The Incidence of Upper Gastrointestinal Complications of Non-steroidal Anti-inflammatory Drugs in Elderly Patients. Medicine Science, Cilt: 3 - Sayı: 1, 1032–1045. https://ajindex.com/articles/277979

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther. 2013;37(3):346-54
  2. Santosh Kumar Yadav, Ajit Kumar Sah, Phoolgen Sah,Rajesh Kumar Jha. Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs in Maxillofacial Trauma Patients: A Review. International Journal of Pharmaceutical & Biological Archives. 2012;3(3):411-4
  3. Schachter M. COX-2 inhibitors and cardiovascular risk. Br J Cardiol. 2003;10(4):288- 92
  4. Davenport HW. Gastric mucosal hemorrhage in dogs. Effects of acid, aspirin, and alcohol. Gastroenterology.1969;56(3):439-49
  5. Kradjan WA. Gastrointestinal Disorders. In: Koda-Kimble MA, Young LY, eds, Applied Therapeutics- The Clinical Use of Drugs, 7th ed. Maryland: Lippincott Williams & Wilkins; 2000
  6. Chan FKL, Leung WK. Peptic-Ulcer disease. Lancet. 2002;360(9337):933-41
  7. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38
  8. Scolnik M, Singh G. Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and costeffectiveness considerations. Open Access Rheumatology: Research and Reviews. 2011;3:53-62
  9. Barry Schlansky & Joo Ha howang. Prevention of nonsteroidal anti-infl amatory druginduced gastropathy J Gastroenterol. 2009;44(Suppl XIX):44-52
  10. Ippokratis Pountos, Theodora Georgouli,Howard Bird&Peter V Giannoudis. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects. International Journal of Interferon, Cytokine and Mediator Research. 2011;3(1):19-27
  11. Lanas, A.; Perez-Aisa, M. & Feu, F. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100(8):1685-93
  12. Lanas, A.; Nern, J. & Esteva, F. Non-steroidal anti-inflammatory drugs and prostaglandin effects on pepsinogen secretion by dispersed human peptic cells. Gut. 1995;36(5):657-63
  13. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009;44(19):44-52
  14. Yuan YH, Wang C, Yuan Y, Hunt RH. Meta-analy